IntegraGen | GenomeWeb

IntegraGen

Laboratoire Cerba was granted the right to develop a tumor expression test based on IntegraGen's proprietary microRNA biomarker.

The planned sequencing platform will be used for both exome and whole-genome sequencing research projects in the fields of cancer, rare diseases, microbiology, and potentially psychiatry.

The company will work with the investigators to examine whether levels of the microRNA can predict patient outcomes to different anti-EGRF therapies.

The hospital will use the new methods with jointly developed bioinformatic analysis techniques to rapidly interpret genomic data. 

IntegraGen will conduct sequencing for theNationalReferenceCenterand the microbiological collections at Institut Pasteur.

Genoma will commercialize the Arisk test outside the US and will provide genetic consulting services and diagnostics services to children with ASD and their parents.

The partners will try to validate the ability of has-miR-31-3p to predict which patients may benefit from anti-EGFR therapy.

The signatures involve a panel of genes that help researchers to distinguish between benign and malignant liver tumors and identify histological subtypes

NEW YORK (GenomeWeb) – Molecular diagnostics firm IntegraGen announced that it is collaborating with the French Intergroup of Thoracic Oncology (IFCT), a network of lung cancer specialists, to investigate the potential of a specific microRNA as a biomarker for advanced non-small cell lung cancer.

NEW YORK (GenomeWeb) – A French group spearheaded by genomics services provider IntegraGen said today that it would collaborate on a project to develop software to support data interpretation of next-generation sequencing of cancer patients.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.